Research outputs
2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
Rowland, T., FitzGerald, R., Challenger, E., Dickinson, L., Else, L. J., Walker, L., . . . AGILE CST‐6 Study Group. (2026). Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.70261
Beyond access: Uncovering hidden public health benefits of participating in experimental medicine trials through detection of clinically significant findings at screening.
Dodd, K., Burhan, H., FitzGerald, R. J., Reuben, M., Briggs, M., Dalzell, J., . . . Walker, L. E. (2026). Beyond access: Uncovering hidden public health benefits of participating in experimental medicine trials through detection of clinically significant findings at screening.. Public health, 254, 106244. doi:10.1016/j.puhe.2026.106244
Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort.
Berthon, W., McGurnaghan, S. J., Blackbourn, L. A. K., Fernandes, A. D. A. S., Walker, L. E., McCrimmon, R. J., . . . Hanlon, P. (2026). Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort.. Diabetic medicine : a journal of the British Diabetic Association, 43(2), e70179. doi:10.1111/dme.70179
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
Abuzour, A. S., Wilson, S. A., Woodall, A. A., Mair, F. S., Aslam, A., Clegg, A., . . . Walker, L. E. (2026). Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study. JOURNAL OF MEDICAL INTERNET RESEARCH, 28. doi:10.2196/74304
2025
CHATD Questionnaire: Development, Validation and Evaluation of Child and Parent Attitudes Towards Deprescribing
A NASSS framework-guided systematic review and exploratory modelling of digital health interventions for polypharmacy management in older adults.
Vamadevan, A., Vijayan, V., Cole, C., Jayasudha, K., Yusuf, N., & Walker, L. E. (2025). A NASSS framework-guided systematic review and exploratory modelling of digital health interventions for polypharmacy management in older adults.. BMC geriatrics, 25(1), 1032. doi:10.1186/s12877-025-06602-4
An automation framework for clinical codelist development validated with UK data from patients with multiple long-term conditions
Aslam, A., Walker, L., Abaho, M., Cant, H., O'Connell, M., Abuzour, A. S., . . . Relton, S. D. (2025). An automation framework for clinical codelist development validated with UK data from patients with multiple long-term conditions. BMC MEDICAL RESEARCH METHODOLOGY, 25(1). doi:10.1186/s12874-025-02541-1
Challenges to nursing leadership in research and academia in the UK: A systematic narrative review
Vamadevan, A., Vijayan, V., Jayasudha, K., Varghese, S., Eboh, O., Karthikeyan, A., . . . Walker, L. (2025). Challenges to nursing leadership in research and academia in the UK: A systematic narrative review. INTERNATIONAL JOURNAL OF NURSING STUDIES ADVANCES, 9. doi:10.1016/j.ijnsa.2025.100411
Implementing and evaluating a development pathway for early-career research nurses.
Vamadevan, A., Lyon, R., Varghese, S., Eboh, O., Thomas, H., Cole, C., . . . Fitzgerald, R. (2025). Implementing and evaluating a development pathway for early-career research nurses.. Nursing management (Harrow, London, England : 1994). doi:10.7748/nm.2025.e2188
The anticholinergic medication index and dementia risk: evidence from the UK Biobank and All of Us research program
Asiimwe, I. G., Best, K., Sofat, R., Todd, O. M., Walker, L., Jorgensen, A. L., . . . Pirmohamed, M. (2025). The anticholinergic medication index and dementia risk: evidence from the UK Biobank and All of Us research program. AGE AND AGEING, 54(11). doi:10.1093/ageing/afaf326
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.
Challenger, E., Else, L., Dickinson, L., Rowland, T., Wood, W., Hale, C., . . . Khoo, S. (2025). Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.. British journal of clinical pharmacology, 91 Suppl 1, 22. doi:10.1002/bcp.70233
Assessing ChatGPT's capability in understanding and reporting antiretroviral therapy drug-drug interaction effects: Quantitative and qualitative results from the ACCURATE-DDI study
Ready, E., Patterson, C., Gibbons, S., Yoong, D., Marzolini, C., Walker, L., & Tseng, A. (2025). Assessing ChatGPT's capability in understanding and reporting antiretroviral therapy drug-drug interaction effects: Quantitative and qualitative results from the ACCURATE-DDI study. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 91, 16-17. doi:10.1002/bcp.70223
Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS-CoV-2: AGILE CST-3a/b
Thompson, B., Else, L., Amara, A., Reynolds, H., Lyon, R., Chiong, J., . . . Khoo, S. (2025). Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS-CoV-2: AGILE CST-3a/b. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 91, 21-22. doi:10.1002/bcp.70232
<i>APOE</i> Genotype and Statin Response: Evidence From the UK Biobank and All of Us Program
Asiimwe, I. G., Jorgensen, A. L., & Pirmohamed, M. (2025). <i>APOE</i> Genotype and Statin Response: Evidence From the UK Biobank and All of Us Program. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 18(8). doi:10.1111/cts.70314
Establishing reference ranges for circulating biomarkers of drug-induced liver injury in healthy human volunteers<SUP>1</SUP>
Jorgensen, A. L., Korver, S., Schofield, A., Howell, L., Clarke, J. I., Walker, L. E., . . . Pirmohamed, M. (2025). Establishing reference ranges for circulating biomarkers of drug-induced liver injury in healthy human volunteers<SUP>1</SUP>. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 91(5), 1361-1369. doi:10.1111/bcp.16371
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study (Preprint)
Mobilising UK Data and AI for All with a National Grid of Civic Learning Systems
Buchan, I., Ainsworth, J., Angione, C., Ardern, K., Atkinson, K., Ball, S., . . . Zhang, X. (2025). Mobilising UK Data and AI for All with a National Grid of Civic Learning Systems (2025/03). https://www.thenhsa.co.uk/about/publications/: Northern Health Science Alliance. Retrieved from https://www.thenhsa.co.uk/
'Flattened, fattened, and forgotten': the 'dis-integrated' care of patients prescribed antipsychotics in the UK
Woodall, A., Buchan, I., Walker, L. E., Sheard, S., Fu, Y., Joyce, D., . . . Mair, F. S. (2025). 'Flattened, fattened, and forgotten': the 'dis-integrated' care of patients prescribed antipsychotics in the UK. BRITISH JOURNAL OF GENERAL PRACTICE, 75(750), 9-10. doi:10.3399/bjgp25X740397
Adapting citizens' jury methodology for use in Uganda: use of creative arts as a tool in deliberative, participatory research
Waitt, C., Nakyeyune, L., Ashaba, A., Ahebwa, S., Nakijoba, R., Asiimwe, S. P., . . . Walker, L. E. (2025). Adapting citizens' jury methodology for use in Uganda: use of creative arts as a tool in deliberative, participatory research. INTERNATIONAL JOURNAL OF SOCIAL RESEARCH METHODOLOGY, 28(4), 425-434. doi:10.1080/13645579.2024.2396371
Antipsychotic management in general practice: serial cross-sectional study (2011-2020)
Woodall, A., Gampel, A., Walker, L. E., Mair, F. S., Sheard, S., Symon, P., & Buchan, I. (2025). Antipsychotic management in general practice: serial cross-sectional study (2011-2020). BRITISH JOURNAL OF GENERAL PRACTICE, 75(750), e68-e79. doi:10.3399/BJGP.2024.0367
WITHDRAWN: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers.
Francis, B., Clarke, J. I., Walker, L. E., Brillant, N., Jorgensen, A. L., Park, B. K., . . . Antoine, D. J. (2018). WITHDRAWN: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers.. Journal of hepatology, S0168-8278(18)32042-7. doi:10.1016/j.jhep.2018.04.024
2024
Rapid and non-invasive analysis of paracetamol overdose using paper arrow-mass spectrometry: a prospective observational study
Zhou, Y., Dliso, S., Craske, J., Gill, A., Bracken, L., Landa, K., . . . Maher, S. (2024). Rapid and non-invasive analysis of paracetamol overdose using paper arrow-mass spectrometry: a prospective observational study. BMC Medicine, 22(1). doi:10.1186/s12916-024-03776-3
Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations.
Walker, L. E., Stackpoole, M., Hodge, D., & FitzGerald, R. (2024). Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations.. British journal of clinical pharmacology. doi:10.1111/bcp.16073
Late Breaking Abstract - Exciting phase 1 data on RESP-X, a novel monoclonal antibody targeting a key virulence mechanism of Pseudomonas aeruginosa, with potential as a treatment to reduce exacerbations in non-CF bronchiectasis
Leonard, C., Savage, V., Ooi, N., Dobmeyer, J., Lindsay, D., Walker, L., & Fitzgerald, R. (2024). Late Breaking Abstract - Exciting phase 1 data on RESP-X, a novel monoclonal antibody targeting a key virulence mechanism of Pseudomonas aeruginosa, with potential as a treatment to reduce exacerbations in non-CF bronchiectasis. In EUROPEAN RESPIRATORY JOURNAL Vol. 64. doi:10.1183/13993003.congress-2024.OA2783
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti-<i>Wolbachia</i> Candidate Macrofilaricide
Devereux, G., Bula, M., Tripp, K., Fitzgerald, R., Eraut, N., Alam, M. S., . . . Ward, S. A. (2024). A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti-<i>Wolbachia</i> Candidate Macrofilaricide. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 13(9), 1071-1081. doi:10.1002/cpdd.1441
Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee
Hilmer, S. N., Schwartz, J., Petrovic, M., Walker, L. E., Thuermann, P., & Le Couteur, D. G. (2024). Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 72(9), 2942-2950. doi:10.1111/jgs.18826
A qualitative exploration of barriers to efficient and effective structured medication reviews in primary care: Findings from the DynAIRx study
Abuzour, A. S., Wilson, S. A., Woodall, A. A., Mair, F. S., Clegg, A., Shantsila, E., . . . Walker, L. E. (2024). A qualitative exploration of barriers to efficient and effective structured medication reviews in primary care: Findings from the DynAIRx study. PLOS ONE, 19(8). doi:10.1371/journal.pone.0299770
Antipsychotic management in general practice: serial cross-sectional study (2011-2020)
Incorporating Transgender and nonbinary Participants in Phase 1 Clinical Drug Trials: Current Knowledge Gaps and Considerations for Phase 1 Studies
Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom.
Woodall, A. A., Abuzour, A. S., Wilson, S. A., Mair, F. S., Buchan, I., Sheard, S. B., . . . Walker, L. E. (2024). Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom.. PloS one, 19(3), e0294974. doi:10.1371/journal.pone.0294974
What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis.
Prokopidis, K., Testa, G. D., Veronese, N., Dionyssiotis, Y., McLean, J., Walker, L. E., & Sankaranarayanan, R. (2024). What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis.. Journal of frailty, sarcopenia and falls, 9(1), 51-65. doi:10.22540/jfsf-09-051
Genetic Determinants of Thiazide-Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances - A Genome-Wide Evaluation of the UK Biobank.
Asiimwe, I. G., Walker, L., Sofat, R., Jorgensen, A. L., Pirmohamed, M., & Multimorbidity Mechanism and Therapeutic Research Collaborative (MMTRC). (2024). Genetic Determinants of Thiazide-Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances - A Genome-Wide Evaluation of the UK Biobank.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.3229
The status of drug evaluation in older adults in the United Kingdom: Bridging the representation gap.
Walker, L. E., & Pirmohamed, M. (2024). The status of drug evaluation in older adults in the United Kingdom: Bridging the representation gap.. Journal of the American Geriatrics Society. doi:10.1111/jgs.18817
Public Attitudes Towards Access to Health Data for Research Purposes Through Citizens' Jury in Uganda
Walker, L. E., Nakyeyune, L., Ashaba, A., Ahebwa, S., Nakijoba, R., Asiimwe, S. P., . . . Waitt, C. (2024). Public Attitudes Towards Access to Health Data for Research Purposes Through Citizens' Jury in Uganda. MEDINFO 2023 - THE FUTURE IS ACCESSIBLE, 310, 129-133. doi:10.3233/SHTI230941
Advantages and challenges of <scp>AI</scp> in enhancing healthcare equity
Okenyi, E., & Walker, L. (2024). Advantages and challenges of <scp>AI</scp> in enhancing healthcare equity. Prescriber, 35(1), 5-8. doi:10.1002/psb.2108
Developing SysteMatic: Prevention, precision and equity by design for people living with multiple long-term conditions
Mair, F. S., Nickpour, F., Nicholl, B., Macdonald, S., Joyce, D. W., Cooper, J., . . . Buchan, I. (2024). Developing SysteMatic: Prevention, precision and equity by design for people living with multiple long-term conditions. JOURNAL OF MULTIMORBIDITY AND COMORBIDITY, 14. doi:10.1177/26335565241272682
Improving Pre-trained Language Model Sensitivity via Mask Specific losses: A case study on Biomedical NER
Abaho, M., Bollegala, D., Leeming, G., Joyce, D., & Buchan, I. E. (2024). Improving Pre-trained Language Model Sensitivity via Mask Specific losses: A case study on Biomedical NER. In PROCEEDINGS OF THE 2024 CONFERENCE OF THE NORTH AMERICAN CHAPTER OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS: HUMAN LANGUAGE TECHNOLOGIES, VOL 1: LONG PAPERS (pp. 5013-5029). Retrieved from https://www.webofscience.com/
Stroke Pharmacogenetics
Walker, L. E., Stewart, A., Pirmohamed, S. M., Meschia, J. F., & Kinne, F. B. (2024). Stroke Pharmacogenetics. In Stroke Genetics (pp. 423-508). Springer International Publishing. doi:10.1007/978-3-031-41777-1_17
2023
Management of Antipsychotics in Primary Care: Insights from Healthcare Professionals and Policy Makers in the UK
How might dynamic artificial intelligence (DynAIRx) be used to support prescribing to ensure efficient medication reviews?
Abuzour, A., Wilson, S., Woodall, A., Mair, F., Bollegala, D., Cant, H., . . . Walker, L. (2023). How might dynamic artificial intelligence (DynAIRx) be used to support prescribing to ensure efficient medication reviews?. American Academy of Family Physicians. doi:10.1370/afm.22.s1.4823
Immunomodulatory interventions for focal epilepsy.
Panebianco, M., Walker, L., & Marson, A. G. (2023). Immunomodulatory interventions for focal epilepsy.. The Cochrane database of systematic reviews, 10, CD009945. doi:10.1002/14651858.cd009945.pub3
ATTITUDES OF CHILDREN AND YOUNG PEOPLE AND THEIR PARENTS TOWARDS POLYPHARMACY - PILOT STUDY
Moss, J., Rashed, A., Walker, L., & Hawcutt, D. (2023). ATTITUDES OF CHILDREN AND YOUNG PEOPLE AND THEIR PARENTS TOWARDS POLYPHARMACY - PILOT STUDY. In ARCHIVES OF DISEASE IN CHILDHOOD Vol. 108 (pp. A11-A12). doi:10.1136/archdischild-2023-ESDPPP.34
Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis
Braithwaite, E., Todd, O. M., Atkin, A., Hulatt, R., Tadrous, R., Alldred, D. P., . . . Clegg, A. (2023). Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis. AGE AND AGEING, 52(9). doi:10.1093/ageing/afad176
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
Challenger, E., Penchala, S. D., Hale, C., Fitzgerald, R., Walker, L., Reynolds, H., . . . Else, L. (2023). Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233. doi:10.1016/j.jpba.2023.115436
Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide?
Walker, L. E., & Pirmohamed, M. (2023). Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide?. Drug and therapeutics bulletin, 61(6), 87-91. doi:10.1136/dtb.2022.000050
POINT PREVALENCE STUDY OF PAEDIATRIC POLYPHARMACY
Moss, J., Rashed, A., Jensen, J., Wilson, J., Walker, L., & Hawcutt, D. (2023). POINT PREVALENCE STUDY OF PAEDIATRIC POLYPHARMACY. In ARCHIVES OF DISEASE IN CHILDHOOD Vol. 108 (pp. A8). doi:10.1136/archdischild-2023-ESDPPP.25
Artificial Intelligence for Multiple Long-term conditions (AIM): A consensus statement from the NIHR AIM consortia
Dambha-Miller, H., Farmer, A., Nirantharakumar, K., Jackson, T., Yau, C., Walker, L., . . . Guthrie, B. (2023). Artificial Intelligence for Multiple Long-term conditions (AIM): A consensus statement from the NIHR AIM consortia. doi:10.3310/nihropenres.1115210.1
Ethnic and racial diversity in early‐phase trial design
Okenyi, E., & Walker, L. (2023). Ethnic and racial diversity in early‐phase trial design. Prescriber, 34(4), 27-30. doi:10.1002/psb.2056
Cardiovascular risk estimation in rural psychiatric inpatient populations: Cross-sectional preliminary study
Woodall, A., Prosser, A., Griffiths, M., Shooter, B., Garfitt, J., Walker, L., & Buchan, I. (2023). Cardiovascular risk estimation in rural psychiatric inpatient populations: Cross-sectional preliminary study. PSYCHIATRY RESEARCH COMMUNICATIONS, 3(1). doi:10.1016/j.psycom.2023.100103
Combinations of medicines in patients with polypharmacy aged 65-100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions.
Fahmi, A., Wong, D., Walker, L., Buchan, I., Pirmohamed, M., Sharma, A., . . . van Staa, T. P. (2023). Combinations of medicines in patients with polypharmacy aged 65-100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions.. PloS one, 18(2), e0281466. doi:10.1371/journal.pone.0281466
Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study
Kuan, V., Denaxas, S., Patalay, P., Nitsch, D., Mathur, R., Gonzalez-Izquierdo, A., . . . MMTRC. (2023). Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. LANCET DIGITAL HEALTH, 5(1), E16-E27. doi:10.1016/S2589-7500(22)00187-X
The novel <scp>siRNA</scp> inclisiran and population health management
Walker, L. E. (2023). The novel <scp>siRNA</scp> inclisiran and population health management. Prescriber, 34(1), 33-35. doi:10.1002/psb.2037
2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
Donovan-Banfield, I., Penrice-Randal, R., Goldswain, H., Rzeszutek, A. M., Pilgrim, J., Bullock, K., . . . Fletcher, T. (2022). Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-34839-9
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2
Cardiovascular risk in a rural psychiatric inpatient population: Retrospective case cohort study
A guide to prescribing antidepressants in primary care
Woodall, A., & Walker, L. (2022). A guide to prescribing antidepressants in primary care. Prescriber, 33(8-9), 11-18. doi:10.1002/psb.2006
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance
Essa, H., Walker, L., Mohee, K., Oguguo, C., Douglas, H., Kahn, M., . . . Sankaranarayanan, R. (2022). Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance. OPEN HEART, 9(2). doi:10.1136/openhrt-2022-001979
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions
Osanlou, R., Walker, L., Hughes, D. A., Burnside, G., & Pirmohamed, M. (2022). Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ OPEN, 12(7). doi:10.1136/bmjopen-2021-055551
Paediatric polypharmacy and deprescribing: the views of UK healthcare professionals
Moss, J. G., Young, D., Rashed, A. N., Walker, L. E., & Hawcutt, D. B. (2023). Paediatric polypharmacy and deprescribing: the views of UK healthcare professionals. ARCHIVES OF DISEASE IN CHILDHOOD, 108(1), 72-73. doi:10.1136/archdischild-2022-323827
CHARACTERISING DISEASE AND PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE AND MULTIMORBIDITY: A SINGLE-CENTRE DESCRIPTIVE COHORT STUDY
Bahar, J., Saied, S., Heron, O., Mashida, K., Akpan, A., Walker, L., . . . Sankaranarayanan, R. (2022). CHARACTERISING DISEASE AND PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE AND MULTIMORBIDITY: A SINGLE-CENTRE DESCRIPTIVE COHORT STUDY. In HEART Vol. 108 (pp. A84). doi:10.1136/heartjnl-2022-BCS.113
Sodium-glucose co-transporter-2 inhibitors in the non-diabetic heart failure patient
Essa, H., Walker, L., & Sankaranarayanan, R. (2022). Sodium-glucose co-transporter-2 inhibitors in the non-diabetic heart failure patient. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88(6), 2566-2570. doi:10.1111/bcp.15085
A European cross-sectional survey to investigate how involved doctors training in clinical pharmacology are in drug concentration monitoring
Green, T. J., Walker, L. E., & Turner, R. M. (2022). A European cross-sectional survey to investigate how involved doctors training in clinical pharmacology are in drug concentration monitoring. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. doi:10.1007/s00228-022-03316-z
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199
DEVELOPMENT OF THE ANTICHOLINERGIC MEDICATION INDEX (ACMI)
Best, K., Alderson, S., Alldred, D., Bonnet, L., Buchan, I., Butters, O., . . . Clegg, A. (2022). DEVELOPMENT OF THE ANTICHOLINERGIC MEDICATION INDEX (ACMI). In AGE AND AGEING Vol. 51. doi:10.1093/ageing/afac035.825
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463
Triple antithrombotic therapy and dual therapy - What is the evidence base?
Essa, H., Sankaranarayanan, R., & Walker, L. (2022). Triple antithrombotic therapy and dual therapy - What is the evidence base?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. doi:10.1111/bcp.15257
Effectiveness of a WHO self-help psychological intervention for preventing mental disorders among Syrian refugees in Turkey: a randomized controlled trial
Acarturk, C., Uygun, E., Ilkkursun, Z., Carswell, K., Tedeschi, F., Batu, M., . . . Barbui, C. (2022). Effectiveness of a WHO self-help psychological intervention for preventing mental disorders among Syrian refugees in Turkey: a randomized controlled trial. WORLD PSYCHIATRY, 21(1), 88-95. doi:10.1002/wps.20939
Multispecialty multidisciplinary input into comorbidities in heart failure reduces hospitalisation and clinic attendance
Polypharmacy in Older People With Heart Failure: Roles of the Geriatrician and Pharmacist
Stefil, M., Dixon, M., Bahar, J., Saied, S., Mashida, K., Heron, O., . . . Sankaranarayanan, R. (2022). Polypharmacy in Older People With Heart Failure: Roles of the Geriatrician and Pharmacist. CARDIAC FAILURE REVIEW, 8. doi:10.15420/cfr.2022.14
The DynAIRx Project Protocol: Artificial Intelligence for dynamic prescribing optimisation and care integration in multimorbidity
Walker, L. E., Abuzour, A. S., Bollegala, D., Clegg, A., Gabbay, M., Griffiths, A., . . . Buchan, I. (2022). The DynAIRx Project Protocol: Artificial Intelligence for dynamic prescribing optimisation and care integration in multimorbidity. JOURNAL OF MULTIMORBIDITY AND COMORBIDITY, 12. doi:10.1177/26335565221145493
2021
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4
Concise advice: Introducing a new clinically focused BJCP series on evidence-based (de)prescribing in challenging situations
Walker, L. E., & Cremers, S. (2021). Concise advice: Introducing a new clinically focused BJCP series on evidence-based (de)prescribing in challenging situations. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(12), 4484-4487. doi:10.1111/bcp.15093
Long-term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?
Walker, L. E., & Cooper, C. (2021). Long-term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(12), 4877-4879. doi:10.1111/bcp.15110
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva
Amara, A., Penchala, S. D., Else, L., Hale, C., FitzGerald, R., Walker, L., . . . Khoo, S. (2021). The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206. doi:10.1016/j.jpba.2021.114356
High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study
Walker, L. E., Sills, G. J., Jorgensen, A., Alapirtti, T., Peltola, J., Brodie, M. J., . . . Pirmohamed, M. (2021). High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. EPILEPSIA. doi:10.1111/epi.17116
One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings
Essa, H., Oguguo, E., Douglas, H., Foster, A., Walker, L., Hadcroft, J., . . . Sankaranarayanan, R. (2021). One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings. European Heart Journal, 42(Supplement_1). doi:10.1093/eurheartj/ehab724.0971
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
ONE YEAR OUTCOMES OF HEART FAILURE MULTISPECIALTY MULTIDISCIPLINARY TEAM VIRTUAL MEETINGS
Essa, H., Oguguo, E., Douglas, H., Foster, A., Walker, L., Hadcroft, J., . . . Sankaranarayanan, R. (2021). ONE YEAR OUTCOMES OF HEART FAILURE MULTISPECIALTY MULTIDISCIPLINARY TEAM VIRTUAL MEETINGS. In HEART Vol. 107 (pp. A99). doi:10.1136/heartjnl-2021-BCS.129
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
The future of clinical pharmacology in the <scp>NHS</scp>
Walker, L., Bennett, F., Scourfield, A., & Payne, R. (2021). The future of clinical pharmacology in the <scp>NHS</scp>. Prescriber, 32(2), 20-23. doi:10.1002/psb.1893
Avoiding harm from overprescribing: What are the challenges and how do we overcome them?
Walker, L. E., & Mangoni, A. A. (2021). Avoiding harm from overprescribing: What are the challenges and how do we overcome them?. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(1), 6-8. doi:10.1111/bcp.14696
One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings
Essa, H., Oguguo, E., Douglas, H., Foster, A., Walker, L., Hadcroft, J., . . . Sankaranarayanan, R. (2021). One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings. In EUROPEAN HEART JOURNAL Vol. 42 (pp. 971). Retrieved from https://www.webofscience.com/
Sequential Association Rule Mining Revisited: A Study Directed at Relational Pattern Mining for Multi-morbidity
Vincent-Paulraj, A., Burnside, G., Coenen, F., Pirmohamed, M., & Walker, L. (2021). Sequential Association Rule Mining Revisited: A Study Directed at Relational Pattern Mining for Multi-morbidity. In ARTIFICIAL INTELLIGENCE XXXVIII Vol. 13101 (pp. 241-253). doi:10.1007/978-3-030-91100-3_20
2020
Avoiding harm from overprescribing: what are the challenges and how do we overcome them?
Barriers and facilitators to deprescribing in primary care: a systematic review
Doherty, A. J., Boland, P., Reed, J., Clegg, A. J., Stephani, A., Williams, N. H., . . . Walker, L. (2020). Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open, 4(3), 0. doi:10.3399/bjgpopen20X101096
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial
Griffiths, G., Fitzgerald, R., Jaki, T., Corkhill, A., Marwood, E., Reynolds, H., . . . Khoo, S. (2020). AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. TRIALS, 21(1). doi:10.1186/s13063-020-04473-1
2019
Strategies to safely reduce polypharmacy in older people: a systematic review of barriers and facilitators to effective intervention
Hill, R. A., Walker, L., Osanlou, O., Williams, N., & Khedmati Morasae, E. (2019). Strategies to safely reduce polypharmacy in older people: a systematic review of barriers and facilitators to effective intervention. Retrieved from http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019121848
2017
Prospective clinical trials to investigate clinical and molecular biomarkers
Auvin, S., Walker, L. E., Gallentine, W., Jozwiak, S., Tombini, M., & Sills, G. J. (2017). Prospective clinical trials to investigate clinical and molecular biomarkers. EPILEPSIA, 58(S3), 20-26. doi:10.1111/epi.13782
Stroke Pharmacogenetics
Walker, L. E., Stewart, A., & Pirmohamed, S. M. (2017). Stroke Pharmacogenetics. In P. Sharma, & J. F. Meschia (Eds.), Stroke Genetics (pp. 327-410). Springer. doi:10.1007/978-3-319-56210-0_17
2016
A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease
Walker, L., Griffiths, M. J., McGill, F., Lewthwaite, P., Sills, G. J., Jorgensen, A., . . . Pirmohamed, M. (2016). A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease. Biomarkers, 22(7), 635-642. doi:10.1080/1354750X.2016.1265003
WONOEP appraisal: Molecular and cellular biomarkers for epilepsy
Walker, L. E., Janigro, D., Heinemann, U., Riikonen, R., Bernard, C., & Patel, M. (2016). WONOEP appraisal: Molecular and cellular biomarkers for epilepsy. EPILEPSIA, 57(9), 1354-1362. doi:10.1111/epi.13460
2015
CLINICAL PHARMACOLOGY EDUCATION IN EUROPE: A TIME TO ACT
Penataro, J. S., Fernandez, J., Walker, L., Aydin, B., Holm, J., Geijteman, E. C. T., . . . Ezzeldin, M. (2015). CLINICAL PHARMACOLOGY EDUCATION IN EUROPE: A TIME TO ACT. CLINICAL THERAPEUTICS, 37(8), E17. doi:10.1016/j.clinthera.2015.05.058
Personalized medicine approaches in epilepsy
Walker, L. E., Mirza, N., Yip, V. L. M., Marson, A. G., & Pirmohamed, M. (2015). Personalized medicine approaches in epilepsy. JOURNAL OF INTERNAL MEDICINE, 277(2), 218-234. doi:10.1111/joim.12322
2014
Adverse Drug Reactions
Walker, L., Yip, V., & Pirmohamed, M. (2014). Adverse Drug Reactions. In Handbook of Pharmacogenomics and Stratified Medicine (pp. 405-435). Elsevier. doi:10.1016/b978-0-12-386882-4.00020-7
High mobility group box 1 in the inflammatory pathogenesis of epilepsy: profiling circulating levels after experimental and clinical seizures
Walker, L., Tse, K., Ricci, E., Thippeswamy, T., Sills, G. J., White, S. H., . . . Pirmohamed, M. (2014). High mobility group box 1 in the inflammatory pathogenesis of epilepsy: profiling circulating levels after experimental and clinical seizures. LANCET, 383, 105. Retrieved from https://www.webofscience.com/
Epilepsy and the inflammasome: Targeting inflammation as a novel therapeutic strategy for seizure disorders
Edye, M. E., Walker, L. E., Sills, G. J., Allan, S. M., & Brough, D. (2014). Epilepsy and the inflammasome: Targeting inflammation as a novel therapeutic strategy for seizure disorders. Inflammasome, 1(1). doi:10.2478/infl-2014-0004
Chapter 20 Adverse Drug Reactions
Walker, L., Yip, V., & Pirmohamed, M. (2014). Chapter 20 Adverse Drug Reactions. In Handbook of Pharmacogenomics and Stratified Medicine (pp. 405-435). Elsevier. doi:10.1016/b978-0-12-386882-4.00020-7
2013
Immunomodulatory interventions for focal epilepsy syndromes
Walker, L., Pirmohamed, M., & Marson, A. G. (2013). Immunomodulatory interventions for focal epilepsy syndromes. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (6). doi:10.1002/14651858.CD009945.pub2
Stroke Pharmacogenetics
Walker, L. E., Stewart, A., & Pirmohamed, M. (2013). Stroke Pharmacogenetics. In Stroke Genetics (pp. 223-297). Springer London. doi:10.1007/978-0-85729-209-4_14
2012
Immunomodulatory interventions for focal epilepsy syndromes
Walker, L., Pirmohamed, M., & Marson, A. G. (2012). Immunomodulatory interventions for focal epilepsy syndromes. In L. Walker (Ed.). John Wiley & Sons, Ltd. doi:10.1002/14651858.cd009945
Inflammation and Epilepsy: The Foundations for a New Therapeutic Approach in Epilepsy?
Walker, L., & Sills, G. J. (2012). Inflammation and Epilepsy: The Foundations for a New Therapeutic Approach in Epilepsy?. EPILEPSY CURRENTS, 12(1), 8-12. doi:10.5698/1535-7511-12.1.8
2011
'Septrin psychosis' among renal transplant patients with <i>Pneumocystis jirovecii</i> pneumonia
Walker, L. E., Thomas, S., McBride, C., Howse, M., Turtle, L. C. W., Vivancos, R., . . . Beadsworth, M. B. J. (2011). 'Septrin psychosis' among renal transplant patients with <i>Pneumocystis jirovecii</i> pneumonia. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(5), 1117-1119. doi:10.1093/jac/dkr050
'Septrin psychosis' among renal transplant patients with Pneumocystis jirovecii pneumonia.
Walker, L. E., Thomas, S., McBride, C., Howse, M., Turtle, L. C. W., Vivancos, R., . . . Beadsworth, M. B. J. (2011). 'Septrin psychosis' among renal transplant patients with Pneumocystis jirovecii pneumonia.. The Journal of antimicrobial chemotherapy, 66(5), 1117-1119. doi:10.1093/jac/dkr050
Voltage-Gated, Potassium-Channel Antibody-Associated Limbic Encephalitis Presenting as Acute Psychosis
Ganguli, A., Fitzgerald, R., Walker, L., Beadsworth, M., & Mwandumba, H. C. (2011). Voltage-Gated, Potassium-Channel Antibody-Associated Limbic Encephalitis Presenting as Acute Psychosis. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 23(2), E32-E34. Retrieved from https://www.webofscience.com/
2009
Spontaneous Hemothorax Following Anticoagulation with Low-Molecular-Weight Heparin
Ganguli, A., Walker, L., FitzGerald, R. J., & Pirmohamed, M. (2009). Spontaneous Hemothorax Following Anticoagulation with Low-Molecular-Weight Heparin. ANNALS OF PHARMACOTHERAPY, 43(9), 1528-1531. doi:10.1345/aph.1L542
Managing alcohol withdrawal syndromes: the place of guidelines
Walker, L., Brown, P., Beeching, N. J., & Beadsworth, M. B. J. (2009). Managing alcohol withdrawal syndromes: the place of guidelines. In BRITISH JOURNAL OF HOSPITAL MEDICINE Vol. 70 (pp. 444-+). doi:10.12968/hmed.2009.70.8.43549
SCG3 Transcript in Peripheral Blood Is a Prognostic Biomarker for REST-Deficient Small Cell Lung Cancer
Moss, A. C., Jacobson, G. M., Walker, L. E., Blake, N. W., Marshall, E., & Coulson, J. M. (2009). SCG3 Transcript in Peripheral Blood Is a Prognostic Biomarker for REST-Deficient Small Cell Lung Cancer. CLINICAL CANCER RESEARCH, 15(1), 274-283. doi:10.1158/1078-0432.CCR-08-1163